Torikai, Hiroki
Mi, Tiejuan
Gragert, Loren
Maiers, Martin
Najjar, Amer
Ang, Sonny
Maiti, Sourindra
Dai, Jianliang
Switzer, Kirsten C.
Huls, Helen
Dulay, Gladys P.
Reik, Andreas
Rebar, Edward J.
Holmes, Michael C.
Gregory, Philip D.
Champlin, Richard E.
Shpall, Elizabeth J.
Cooper, Laurence J. N.
Article History
Received: 30 October 2015
Accepted: 27 January 2016
First Online: 23 February 2016
Competing interests
: Some of the technology described was advanced through research conducted at the MD Anderson Cancer Center by LJNC. Both MD Anderson Cancer Center and LJNC, HT, TM, AN, SA, SM, KCS and HH have a financial interest in ZIOPHARM Oncology, Inc. and Intrexon Corporation. On May 7, 2015, Dr. Cooper was appointed as the Chief Executive Officer at ZIOPHARM. Dr. Cooper is now a Visiting Scientist at MD Anderson where he will continue to supervise the development of this technology. GPD, AR, EJR, MCH and PDG are current or past employees of Sangamo Biosciences, Inc.